Acadia Pharmaceuticals Appoints Bristol Myers Squibb Veteran to Lead Rare Disease Commercial Strategy
Key Insights
Acadia Pharmaceuticals has appointed Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise, bringing over 20 years of pharmaceutical industry experience.
McMillan-Youngblood previously served as Senior Vice President and Business Unit Head, U.S. Oncology at Bristol Myers Squibb (search), where she oversaw successful rare tumor acquisitions and product launches.
Her appointment focuses on maximizing DAYBUE's commercial potential and preparing for future rare disease product launches as Acadia expands its portfolio.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced on May 27, 2025, the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. The strategic hire positions the company to strengthen its commercial capabilities for DAYBUE and future rare disease product launches.
Executive Leadership Addition
McMillan-Youngblood joins Acadia's commercial leadership team with a mandate to maximize DAYBUE's potential and prepare for upcoming product launches as the company expands its rare disease portfolio. "We are delighted to welcome Allyson to Acadia," said Catherine Owen Adams, Chief Executive Officer. "She brings a remarkable breadth of experience across U.S. and global sales and marketing roles, with a proven track record of delivering strong commercial results."
Extensive Industry Experience
The new executive brings more than 20 years of global pharmaceutical industry experience, including various sales positions in both primary care and specialty sectors at Pfizer, and significant commercial roles at Bristol Myers Squibb (search) (BMS). Her expertise spans multiple therapeutic areas including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders.
Most recently, McMillan-Youngblood served as Senior Vice President and Business Unit Head, U.S. Oncology at BMS, where she provided strategic oversight for two major acquisitions in rare tumors. This role resulted in successful product launches and significant market share growth, demonstrating her capability in the rare disease space that directly aligns with Acadia's strategic focus.
Strategic Focus on Rare Disease Growth
"Her leadership across therapeutic areas—including oncology, immunology, CNS, infectious disease, cardiovascular and metabolic disorders—as well as her experience specifically in rare oncology, will be invaluable as we grow the DAYBUE brand and advance our pipeline to bring new therapies to patients in need," Adams noted.
McMillan-Youngblood expressed enthusiasm about joining the company, stating: "I am excited to join Acadia Pharmaceuticals. Acadia has a strong commitment to patient care and innovation, and I look forward to working with the team to drive DAYBUE growth and prepare to bring new therapies to patients with rare diseases."
Company Portfolio and Pipeline
Acadia has established itself in the neuroscience space, having developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis (search) and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome (search). The company's clinical-stage development efforts are focused on Prader-Willi syndrome (search), Alzheimer's disease psychosis (search) and multiple other programs targeting neuroscience and neuro-rare diseases.
McMillan-Youngblood holds a Bachelor of Science in Business Administration from Florida A&M University and has been consistently recognized for her ability to lead through change and her commitment to improving patient outcomes throughout her career. Beyond her operational expertise, she is recognized as a driven and highly capable leader who fosters an inclusive culture that embraces both strategic and solution-oriented innovation.